TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8267700
Drug: Maintenance resistance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance resistance training twice a week
Study: 4035232
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) alone or associated with conventional antihypertensive therapy
Study: 30021886
Drug: Anti-CTLA-4 therapy
Normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS, GENE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CTLA-4 therapy
Study: 30021886
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (anti-CTLA-4 and anti-PD-1)
Study: 30650288
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC), 3 pills each time, 3 times per day for 3 months
Study: 30641625
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) Sulfate, 0.1 g per tablet, 2 tablets each time, twice per day for 3 months
Study: 22740509
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 g/day for 4 months)
Study: 20173020
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (1 mg/m²·d) for 12 and 24 months
Study: 17908978
Drug: LT plus
Normalized name: BALANCED SALT PLUS SOLN,OPH IRRG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT plus ADV‐TK therapy
Study: 17908978
Drug: LT plus
Normalized name: BALANCED SALT PLUS SOLN,OPH IRRG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT plus ADV‐TK therapy (nonvascular invasion subgroup)
Study: 15796730
Drug: Intravenous antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antivenom (AV)
Study: 15796730
Drug: Intramuscular antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular antivenom (AV)
Study: 12443837
Drug: Ospemifene 25
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 25 mg
Study: 12443837
Drug: Ospemifene 50
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 50 mg
Study: 12443837
Drug: Ospemifene 100
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 100 mg
Study: 12443837
Drug: Ospemifene 200
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 200 mg
Study: 9860407
Drug: Interferon-alpha-2b (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2b (3 MU thrice weekly) and ribavirin (1000-1200 mg/daily per os) for 24 weeks
Study: 9860407
Drug: Interferon-alpha-2b alone
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b alone (6 MU thrice weekly) for 24 weeks
Study: 27422421
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid injection (40 mg methylprednisolone) at monthly intervals for 6 consecutive months
Study: 23060056
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care plus chiropractic manipulative therapy (CMT)
Study: 21903774
Drug: CYP3A4 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4 CC homozygotes plus CYP3A5*3/*3
Study: 21903774
Drug: CYP3A4 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4 CC homozygotes with CYP3A5*3/*3
Study: 21903774
Drug: CYP3A4 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4 CC homozygotes with CYP3A5*1
Study: 18582308
Drug: 15 mg/ml
Normalized name: phenol 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/ml hyperbaric lidocaine
Study: 18582308
Drug: 20 mg/ml
Normalized name: urea 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/ml hyperbaric lidocaine
Study: 12862201
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg daily (candesartan group)
Study: 9346162
Drug: Carbohydrate supplement
Normalized name: carbohydrate supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplement (N = 17)
Study: 2420164
Drug: Ethmozine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine (10 mg/kg/day)
Study: 2420164
Drug: Ethmozine (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine (maintenance therapy)
Study: 19243745
Drug: P along
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P along with 6 mg E(2) valerate vaginally (group C)
Study: 19243745
Drug: P along
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P along with 6 mg E(2) valerate orally (group B)
Study: 18700216
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (general)
Study: 19996309
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin administration
Study: 9589972
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of RA using acupuncture (A)
Study: 3947490
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine 2.7 ml at L2/3 (Group C)
Study: 3947490
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine 2 ml at L3/4 (Group D)
Study: 3947490
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 4 ml at L3/4 (Group B)
Study: 3947490
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine 2.7 ml at L3/4 (Group A)
Study: 28201994
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg once daily or 17.5 mg once weekly)
Study: 26066773
Drug: Thiamine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (300 mg in 0.9% Normal saline solution)
Study: 21733421
Drug: Subcutaneous local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous local anesthetic mixture under the tourniquet
Study: 7506146
Drug: Nimesulide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide treatment for 7 to 10 days
Study: 7506146
Drug: Nimesulide in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide in combination with ambroxol
Study: 26653067
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention with monthly motivational counselling calls and weekly personalised text messages for 12 months
Study: 24566244
Drug: Sevoflurane (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (0.5 to 3.5 vol%) and Remifentanil (0 to 12 ng/ml)
Study: 20121764
Drug: Extra-fine beclomethasone/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily
Study: 20121764
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/S) 500/100 microg daily
Study: 10520055
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 microg, twice daily)
Study: 1675050
Drug: Flurbiprofen sodium
Normalized name: Flurbiprofen Sodium
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen sodium 0.03% (topically administered to one eye)
Study: 1675050
Drug: Placebo (topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (topically administered to the contralateral eye)
Study: 29935595
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (acustimulation/dexamethasone)
Study: 26679243
Drug: Delafloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delafloxacin (300 mg, intravenously, twice daily for 5-14 days)
Study: 26679243
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg, intravenously, twice daily for 5-14 days)
Study: 26679243
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg, intravenously, twice daily for 5-14 days)
Study: 24563440
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen therapy (NBOT)
Study: 17593070
Drug: Pantoprazole granules
Normalized name: pantoprazole Granule Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole granules (40 mg)
Study: 17593070
Drug: Pantoprazole tablets
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole tablets (40 mg)
Study: 14976607
Drug: Praziquantel and
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel and mebendazole (treatment every 3 months)
Study: 10404023
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of lactulose
Study: 10404023
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of lactulose
Study: 2175022
Drug: Traditional multi-vitamin
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional multi-vitamin treatment
Study: 10359410
Drug: Once-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly isoniazid (900 mg) and rifapentine (600 mg)
Study: 10359410
Drug: Twice-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly isoniazid (900 mg) and rifampin (600 mg)
Study: 1850691
Drug: Beet fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet fiber supplementation (16 g added to ordinary diet)
Study: 6121836
Drug: Bromazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (6 mg daily: 1.5 mg at 7 a.m., 1.5 mg at 3 p.m., 3 mg at 11 p.m.)
Study: 6121836
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage pattern as bromazepam)
Study: 15181054
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/d)
Study: 15155303
Drug: IA saline
Normalized name: CVS Milk of Magnesia Saline Laxative 1200mg/15mL Suspension (Mint)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA saline 10 mL
Study: 17138192
Drug: IA saline
Normalized name: CVS Milk of Magnesia Saline Laxative 1200mg/15mL Suspension (Mint)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA saline 1 mL (placebo)
Study: 9886506
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg leuprolide acetate (GnRHa) for ovulation induction
Study: 11403367
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg q.d.
Study: 23622917
Drug: Intra-arterial contrast
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial contrast injection
Study: 23622917
Drug: Intravenous contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast administration
Study: 20639734
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy
Study: 16968504
Drug: IV pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pantoprazole (PAN) 80 mg plus 8 mg/h for 72 h
Study: 16968504
Drug: IV ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ranitidine (RAN) 50 mg plus 6.25 mg/h for 72 h
Study: 9108644
Drug: Trihexyphenidyl (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trihexyphenidyl (8 mg)
Study: 9108644
Drug: Biperiden (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (6 mg)
Study: 8099803
Drug: Metoprolol, 50
Normalized name: Hydrochlorothiazide-Metoprolol, 50 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 50 mg three times daily
Study: 8099803
Drug: Propranolol, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, single 40 mg dose
Study: 2869703
Drug: Lactate infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusions
Study: 2869703
Drug: Chronic alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic alprazolam treatment
Study: 31362262
Drug: EIMD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EIMD group received a treatment to induce muscle damage consisting of a weight lifting protocol directed to the agonist muscles related to the task prior to the pretest and to the learning sessions.
Study: 31362262
Drug: CON group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON group (control group) did not receive the EIMD treatment.
Study: 30218170
Drug: Home intravenous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intravenous (IV) ertapenem
Study: 30218170
Drug: Oral amoxicillin‐clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin‐clavulanate
Study: 26368863
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment responders
Study: 9922346
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 x 10^6 U over 30 to 60 minutes)
Study: 442224
Drug: peptichemio at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptichemio at 1.2 mg/kg twice weekly
Study: 442224
Drug: peptichemio at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptichemio at 0.9 mg/kg twice weekly
Study: 442224
Drug: peptichemio at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptichemio at 1.3 mg/kg once weekly combined with other cytostatic drugs
Study: 27265706
Drug: Lifestyle coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle coaching plus care coordination plus treatment as usual (N=138)
Study: 27265706
Drug: Care coordination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care coordination plus treatment as usual (N=142)
Study: 27265706
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual alone (N=148)
Study: 25124733
Drug: Capsaicin-contained red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin-contained red pepper sauce (acute infusion)
Study: 25124733
Drug: Capsaicin-contained red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin-contained red pepper sauce (repeated infusion)
Study: 21921823
Drug: 2‐nitrooxy ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐nitrooxy ethyl 2‐amino 3‐methylbutanoate gel
Study: 17472154
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluids using a dry IV fluid warmer (normothermia group)
Study: 17472154
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature intravenous fluids (hypothermia group)
Study: 9861410
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of quinine (20 mg/kg)
Study: 9861410
Drug: No loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: No loading dose of quinine
Study: 25574674
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg + 2800 IU cholecalciferol once per week
Study: 20401289
Drug: Daflon (micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon (micronized purified flavonoid fraction) 500 mg (6 tablets daily for 4 days, followed by 2 tablets for 3 days)
Study: 18270352
Drug: Experimental strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental strategy (n = 475): target tidal volumes of 6 mL/kg of predicted body weight, plateau pressures not exceeding 40 cm H2O, recruitment maneuvers, and higher positive end‐expiratory pressures.
Study: 18270352
Drug: Control strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control strategy (n = 508): target tidal volumes of 6 mL/kg of predicted body weight, plateau airway pressures not exceeding 30 cm H2O, and conventional levels of positive end‐expiratory pressure.
Study: 15885294
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU daily oral vitamin D3
Study: 15885294
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg calcium
Study: 15885294
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 800 IU vitamin D3 and 1000 mg calcium
Study: 10974132
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (2 mg through a metered-dose inhaler with a spacer)
Study: 10974132
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2 mg per kilogram of body weight)
Study: 1505150
Drug: Sch 37370
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sch 37370 (5 mg/kg)
Study: 30058829
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 85)
Study: 20444767
Drug: Direct referral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct referral to a cessation clinic (CC)
Study: 18767591
Drug: Tendon‐muscle picking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendon‐muscle picking therapy
Study: 15811059
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and metronidazole (M, 400 mg tid) for 10 days (T1)
Study: 15811059
Drug: SRP, weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP, weekly professional supragingival plaque removal for 3 months (PC) and placebo (T2)
Study: 12395912
Drug: Acemetacin 60
Normalized name: acemetacin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin 60 mg t.i.d.
Study: 7560468
Drug: Nebulized adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized adrenaline (2 mg over 10 min)
Study: 7560468
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (5 mg over 10 min)
Study: 6853746
Drug: fenoterol hydrobromide
Normalized name: Fenoterol hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol hydrobromide (0.5, 1.25, and 2.5 mg)
Study: 6853746
Drug: isoproterenol (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoproterenol (2.8 mg) with phenylephrine (1.25 mg)
Study: 6853746
Drug: isoetharine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoetharine (5 mg) with phenylephrine (1.25 mg)
Study: 21928233
Drug: Bicarbonate treatment
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate treatment group (Bic)
Study: 21928233
Drug: Usual-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-treatment group (no-Bic)
Study: 19397672
Drug: LED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatment with a 590-nm wavelength LED array
Study: 21040410
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg/day for 1 year
Study: 21040410
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/day for 1 year
Study: 12237663
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/d) and Vitamin E (400 IU/d) supplementation
Study: 12237663
Drug: Women at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women at low risk (no supplements)
Study: 1788614
Drug: Gemfibrozil (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (900 mg daily)
Study: 1788614
Drug: Phenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenofibrate (300 mg daily)
Study: 25229779
Drug: Povidone-iodine topical
Normalized name: povidone-iodine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine topical antiseptic
Study: 25229779
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray (1,1,1,3,3 pentafluoropropane and 1,1,1,2‐tetrafluoroethane)
Study: 20144207
Drug: loratadine (antihistamine)
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loratadine (antihistamine)
Study: 12915681
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg/d)
Study: 15938033
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg/d)
Study: 1751798
Drug: alpha-IFN therapy
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-IFN therapy alone
Study: 1751798
Drug: Prednisone priming
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone priming with IFN therapy
Study: 1751798
Drug: IFN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN therapy alone
Study: 6113192
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bd
Study: 6109686
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg tds and 400 mg at night
Study: 25624430
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg daily) and Letrozole (2.5 mg daily)
Study: 30872130
Drug: Folate receptor-positive
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate receptor-positive circulating tumour cells (FR+-CTCs)